After a turbulent year in the gene therapy field, the 3rd Gene Therapy Potency Assay Summit returns at a time when drug developers are increasingly recognizing that it is business-critical to have a robust potency assay to support clinical and commercial progress.
For potency assay experts, there is no other meeting offering in-depth technical discussions with a genuine expert community who are uniting to discuss essential sticking points like phase-appropriate assay development, methodology progress, reducing lot-to-lot variability, and aligning to changing regulatory guidelines.
Engage with analytical leads to discuss shared pain points, new technologies enabling improved predictability, and hear perspectives from those who have been through IND-enabling studies and all the way to commercialization of their gene therapy products.
For potency assay experts, there is no other meeting offering in-depth technical discussions with a genuine expert community who are uniting to discuss essential sticking points like phase-appropriate assay development, methodology progress, reducing lot-to-lot variability, and aligning to changing regulatory guidelines.
Engage with analytical leads to discuss shared pain points, new technologies enabling improved predictability, and hear perspectives from those who have been through IND-enabling studies and all the way to commercialization of their gene therapy products.
